OOIR: Observatory of International Research

Papers

(The median citation count of Current Opinion in Lipidology is 4. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)

Article	Citations
Editorial introductions	91
Familial hypercholesterolemia-Plus: is the metabolic syndrome changing the clinical picture of familial hypercholesterolemia?	82
Alveolar macrophages: guardians of the alveolar lipid galaxy	66
Triglyceride-rich lipoproteins, remnant-cholesterol, and atherosclerotic cardiovascular disease	51
Genetic variation in apolipoprotein A-V in hypertriglyceridemia	43
Angiopoietin-like protein 8: a multifaceted protein instrumental in regulating triglyceride metabolism	37
Ups and downs in PCSK9 inhibition in the cardiovascular arena: a review	35
Genetic determinants of plasma lipids in Greenlanders	31
Polygenic risk scores in familial hypercholesterolemia. Do they have a role?	27
Universal screening for familial hypercholesterolaemia: how can we maximise benefits and minimise potential harm for children and their families?	21
Oxidized LDL receptors: a recent update	20
Familial hypercholesterolemia in children and the importance of early treatment	20
Lipoprotein(a) and peripheral artery disease: contemporary evidence and therapeutic advances	20
The lipid-heart hypothesis from the Seven Countries Study of Cardiovascular Diseases	20
Familial hypercholesterolemia: The nexus of endothelial dysfunction and lipoprotein metabolism in COVID-19	20
Exosomes and lipid metabolism in metabolic and cardiovascular disorders	19
Implementation science and genetic testing for familial hypercholesterolemia	19
Editorial introductions	18
Lipid metabolism during pregnancy: consequences for mother and child	18
Nonalcoholic fatty liver disease: an update	16
Nutrition and its impact on cardiovascular disease	16
The current state of apolipoprotein E in dyslipidemia	15
A new SPRING in lipid metabolism	15
Recent advances in understanding the spectrum of genetic determinants of lipoprotein(a) levels	14
Genetic determinants of pancreatitis risk in hypertriglyceridemia	14

Familial hypercholesterolemia in pregnancy	14
From clinical development to real-world outcomes with inclisiran	13
Editorial introductions	13
The need for national and international registries of patients with elevated lipoprotein(a)	13
High-density lipoprotein functionality, cardiovascular health, and patterns of alcohol consumption: new insights and future perspectives	13
Genetic insights from Greenland: when geography, history and genomics converge	12
The intracellular chylomicron highway: novel insights into chylomicron biosynthesis, trafficking, and secretion	12
ANGPTL3 and ApoC-III inhibitors for treating hypertriglyceridemia in context: horses for courses?	12
APOE and familial hypercholesterolemia	12
The complex pro-atherosclerotic role of lipoprotein(a): a multiplicity of cellular targets	11
Are the lipid-lowering effects of incretin-based therapies relevant for cardiovascular benefit?	11
Evolving guidelines on lipoprotein(a)	11
Beyond cholesterol: linking the conformation of apolipoprotein B to atherogenesis	10
Editorial introductions	10
The emerging role of fat-inducing transcript 2 in endoplasmic reticulum proteostasis and lipoprotein biogenesis	10
Inclisiran: present and future perspectives of a new effective LDL cholesterol-lowering agent	10
In the wake of the Scandinavian Simvastatin Survival Study trial	10
Can small dense LDL cholesterol be estimated from the lipid profile?	10
Distinct roles of size-defined HDL subpopulations in cardiovascular disease	9
Cardiomyocytes, sphingolipids and cardio myotoxicity	9
Newborn screening for lipid disorders	9
Circulating protein and lipid markers of early sepsis diagnosis and prognosis: a scoping review	8
Clinical associations between exercise and lipoproteins	8
The expanding role of lyso-phosphatidylcholine acyltransferase-3 (LPCAT3), a phospholipid remodeling enzyme, in health and disease	8
Genetic testing for familial hypercholesterolemia	8
Altered cardiovascular risk pattern of LDL cholesterol in older adults	8
Pregnancy, cardiovascular health, and microchimerism	8
Genotype–phenotype correlation in a large cohort of pediatric patients with heterozygous and homozygous familial hypercholesterolemia	7
Editorial introductions	7
Dietary fat, telomere length and cognitive function: unravelling the complex relations	7
Strategies for management of patients with elevated lipoprotein(a)	7
The pathophysiology of excess plasma-free cholesterol	7
Assessment of cardiovascular disease risk: a 2023 update	7
Lipidomics in gestational diabetes mellitus	7
Prevention of cardiometabolic diseases through dietary modifications	7
Navigating variants of uncertain significance in genetic dyslipidemia: how to assess and counsel patients	7
The feedback cycles between glucose, amino acids and lipids and alpha cell secretion and their role in metabolic fatty liver disease	7
A contemporary snapshot of familial hypercholesterolemia registries	7
Recent lipoprotein(a) trials	6
Translating guidelines into practice via implementation science: an update in lipidology	6
Understanding the ins and outs of lipoprotein (a) metabolism	6
Proprotein convertase subtilisin/kexin type 9-inhibition across different patient populations	6
The current landscape of prospective proteomics research into dementia using blood-based samples	6
Atherogenic low-density lipoprotein and cardiovascular risk	6
Diagnosis of remnant hyperlipidaemia	6
Predictors of cardiovascular risk in familial hypercholesterolemia	6
HDL and ASCVD: is high HDL-C protective, harmful, or simply misleading?	6
Beyond cellular distress: reframing GDF15 as a lipid-sensitive metabolic signal	6
Remnant cholesterol as a new lipid-lowering target to reduce cardiovascular events	6
Impact of mRNA and protein isoforms in lipoprotein metabolism and how to modulate them	6

How should low-density lipoprotein cholesterol be calculated in 2022?	6
Triglyceride-rich lipoprotein cholesterol and cardiovascular risk	5
Are Lipoprotein(a) levels decreased in insulin resistance and type 2 diabetes?	5
Basic and translational evidence supporting the role of TM6SF2 in VLDL metabolism	5
Editorial introduction	5
Bempedoic acid for nonalcoholic fatty liver disease: evidence and mechanisms of action	5
Regulation of cardiovascular calcification by lipids and lipoproteins	5
Consensus and guidelines on lipoprotein(a) – seeing the forest through the trees	5
Cholesteryl ester transfer protein inhibition: a pathway to reducing risk of morbidity and promoting longevity	5
Resolution of apolipoprotein A1 and A2 proteoforms: their cardiometabolic correlates and implications for future research	5
Lipoprotein(a) in familial hypercholesterolemia	5
Genetics of remnant cholesterol	5
Complex actions of sodium glucose transporter-2 inhibitors on lipids, calcific atherosclerosis, and bone density	5
Lipoprotein (a) in familial hypercholesterolaemia	4
Inflammation in atherosclerosis: a Big Idea that has underperformed so far	4
Orticumab: the potential to harness oxidized LDL to reduce coronary inflammation with plaque-targeted therapy	4
Inflammation and atherosclerotic cardiovascular disease: where do we go from here?	4
G protein-coupled receptor 146: new insights from genetics and model systems	4
PCSK9-directed therapies: an update	4
Emerging regulators of endothelial lipid metabolism in atherosclerosis	4
Novel therapeutic opportunities for familial lecithin:cholesterol acyltransferase deficiency: promises and challenges	4
Editorial introduction	4
Macrophage cannibalism: efferocytosis in atherosclerosis	4
Ultra-processed foods and CKD: a review of evidence, limitations, and future directions	4
Circulating cell-free DNA and its association with cardiovascular disease: what we know and future perspectives	4
Established and potential cardiovascular risk factors in metabolic syndrome: Effect of bariatric surgery	4
Bempedoic acid: new evidence and recommendations on use	4
Editorial introductions	4